HOME > REGULATORY

REGULATORY

Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28

January 23, 2015
NIBIO Chief Pins Hopes on Potential Synergies from Impending Merger

January 22, 2015
NIBIO Completes Development of Prototype Adjuvant Database

January 22, 2015
PAFSC’s Second Committee on Drugs Recommends Approval for Eisai’s Lenvatinib

January 22, 2015
R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017

January 21, 2015
Health Ministry Reveals Guidelines on Research Misconduct

January 20, 2015
R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways

January 20, 2015
Consumer Affairs Agency to Begin Study on Child-Resistant PTP Sheets

January 20, 2015
PAFSC 1st Committee to Discuss Takeda’s Once-Weekly DPP-4 Inhibitor on Jan. 30

January 20, 2015
NIBIO to Launch Project to Collate Compound Libraries, Academic Seeds

January 19, 2015
AMED Chief-to-Be Vows to Overhaul Siloed Research Grants

January 19, 2015
PMDA Head Expresses Full Support for AMED

January 19, 2015
112.8 Billion Yen Allotted to Intractable Disease Measures

January 19, 2015
65 Institutions to Treat Post-HPV Vaccine Adverse Reactions

January 16, 2015
MHLW to Reorganize Health Service Bureau in FY2015

January 16, 2015
LDP’s Takemi Says NHI Prices Will Probably Be Cut for 3 Years in a Row

January 16, 2015
MHLW Approves Plan to Include Hepatitis B Vaccines in Public Vaccination Programs

January 16, 2015
1.9 Billion Yen Allocated to Speed Up Regulatory Reviews

January 15, 2015
124.8 Billion Yen Earmarked in FY2015 Budget for AMED

January 15, 2015
AJMC to Announce Guidelines for Investigator-Led Clinical Trials Next Month

January 15, 2015

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…